The PARP inhibitors represent a novel therapeutic strategy in DNA-repair-deficient tumors, such as triple-negative breast cancer. "PARP inhibitors, which include Sanofi-Aventis's BSI-201 and AstraZeneca's olaparib, could dramatically improve prognoses for the woefully underserved patient subgroups with DNA-repair-deficient tumors" Dr. Murphy said.
Full Article at News-Medical.net